In vitro antioxidant and antigenotoxic potentials of myricetin-3-o-galactoside and myricetin-3-o-rhamnoside from Myrtus communis: modulation of expression of genes involved in cell defence system using cDNA microarray.
Antioxidant activity of myricetin-3-o-galactoside and myricetin-3-o-rhamnoside, isolated from the leaves of Myrtus communis, was determined by the ability of each compound to inhibit xanthine oxidase activity, lipid peroxidation and to scavenge the free radical 1,1-diphenyl-2-picrylhydrazyl. Antimutagenic activity was assessed using the SOS chromotest and the Comet assay. The IC50 values of lipid peroxidation by myricetin-3-o-galactoside and myricetin-3-o-rhamnoside are respectively 160 microg/ml and 220 microg/ml. At a concentration of 100 microg/ml, the two compounds showed the most potent inhibitory effect of xanthine oxidase activity by respectively, 57% and 59%. Myricetin-3-o-rhamnoside was a very potent radical scavenger with an IC50 value of 1.4 microg/ml. Moreover, these two compounds induced an inhibitory activity against nifuroxazide, aflatoxine B1 and H2O2 induced mutagenicity. The protective effect exhibited by these molecules was also determined by analysis of gene expression as response to an oxidative stress using a cDNA micro-array. Myricetin-3-o-galactoside and myricetin-3-o-rhamnoside modulated the expression patterns of cellular genes involved in oxidative stress, respectively (GPX1, TXN, AOE372, SEPW1, SHC1) and (TXNRD1, TXN, SOD1 AOE372, SEPW1), in DNA damaging repair, respectively (XPC, LIG4, RPA3, PCNA, DDIT3, POLD1, XRCC5, MPG) and (TDG, PCNA, LIG4, XRCC5, DDIT3, MSH2, ERCC5, RPA3, POLD1), and in apoptosis (PARP).
Hayder
Nawel
N
Unité de Pharmacognosie/Biologie Moléculaire 99/UR/07-03, Faculté de Pharmacie de Monastir, Rue Avicenne, 5000 Monastir, Tunisia.
Bouhlel
Ines
I
Skandrani
Ines
I
Kadri
Malika
M
Steiman
Régine
R
Guiraud
Pascale
P
Mariotte
Anne-Marie
AM
Ghedira
Kamel
K
Dijoux-Franca
Marie-Geneviève
MG
Chekir-Ghedira
Leila
L
D016587:Antimutagenic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000378:metabolism* / Q000494:pharmacology*; D001713:Biphenyl Compounds; D002470:Cell Survival / Q000187:drug effects; D020552:Comet Assay; D004260:DNA Repair / Q000187:drug effects; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology*; D005697:Galactosides / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D017403:In Situ Hybridization; D020014:K562 Cells; D015227:Lipid Peroxidation / Q000187:drug effects; D008362:Mannosides / Q000494:pharmacology*; D009152:Mutagenicity Tests; D031651:Myrtus / Q000737:chemistry*; D020411:Oligonucleotide Array Sequence Analysis; D010851:Picrates / Q000378:metabolism; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D016587:Antimutagenic Agents; D000975:Antioxidants; D001713:Biphenyl Compounds; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D005419:Flavonoids; D005697:Galactosides; D008362:Mannosides; D010851:Picrates; D010936:Plant Extracts; C529904:myricetin-3-O-galactoside; C529905:myricetin-3-O-rhamnoside; C040015:myricetin; C004931:1,1-diphenyl-2-picrylhydrazyl; D014969:Xanthine Oxidase